This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CML-Living With A Chronic Disease

WHITE PLAINS, N.Y., April 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish-speaking patients with chronic myeloid leukemia (CML). On Wednesday, April 17, from 1:00 to 2:00 PM Eastern Time, international CML expert Dr. Jorge Cortes from The University of Texas MD Anderson Cancer Center will present a free, live telephone/web education program titled CML–Living with a Chronic Disease. This program will be presented simultaneously in Spanish.

Since the advent of targeted therapies, three of which are now approved for the treatment of newly diagnosed chronic phase CML, survival and quality of life for patients with CML has dramatically improved. Recent studies show that more than 90% of newly diagnosed, early stage CML patients can expect to survive long-term. Just as LLS was instrumental in funding the research which led to the development of imatinib (Gleevec ®), LLS is also committed to ensuring that these treatment advances reach all patients. The telephone/web program on April 17 will provide Spanish-speaking patients and caregivers the opportunity to learn about the latest advances in CML treatment and quality of life from one of the leading experts in the field. Dr. Cortes will discuss CML treatment options, as well as the critical importance of treatment adherence and monitoring of treatment response. This program, offered by The Leukemia & Lymphoma Society in collaboration with Abrale and Alianza Latina is supported by grants from Bristol-Myers Squibb and Novartis Oncology. The Leukemia & Lymphoma Society is pleased to offer continuing education credit for nurses and social workers.

To register for the April 17 program CML–Living with a Chronic Disease in Spanish, please visit

To register for CML–Living with a Chronic Disease in English, please visit

For information on other LLS programs, please visit or contact an Information Specialist at (800) 955-4572.

About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET

Contact: Andrea Greif914.821.8958 

SOURCE The Leukemia & Lymphoma Society

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.69 -0.59%
FB $119.49 1.43%
GOOG $711.11 1.40%
TSLA $214.93 1.61%
YHOO $37.23 0.79%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs